AXIM Begins Phase 2 Trial of Cannabinoid Chewing Gum for IBS Symptoms

AXIM Begins Phase 2 Trial of Cannabinoid Chewing Gum for IBS Symptoms
AXIM Biotech has initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for alleviating symptoms of irritable bowel syndrome (IBS). In the case of positive results, the company will "proceed immediately with further trials on our pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease," AXIM CEO George E. Anastassov, MD, said in a press release. The randomized, double-blind, placebo-controlled Phase 2 clinical trial (
Subscribe or to access all post and page content.